Transgene SA (FR:TNG)
:TNG
Earnings Data
Report Date
Apr 29, 2026During Market Hours (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
―Last Year’s EPS
-0.13Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized several strong positives: robust fundraising (EUR 105M), a strengthened balance sheet (EUR 39M debt conversion), compelling Phase I efficacy and durable immunogenicity signals for TG4050 (100% disease-free in treated Phase I patients; 73% immunogenicity with responses persisting 24 months), encouraging BT-001 combination data, and a clear plan for manufacturing and regulatory readiness. Counterbalancing these highlights are timing and operational risks (GMP readiness targeted Q3 2027), immature/pending pivotal readouts (Phase II 2-year DFS not yet available), ongoing cash burn (~EUR 38.2M in 2025) and some dependence on broader field validation. Overall, the positive clinical signals and strengthened financial position outweigh the execution and timing risks at this stage.Company Guidance
Successful Fundraising and Balance Sheet Strengthening
Raised approximately EUR 105 million in December 2025 and converted EUR 39 million of debt into equity, leaving the company virtually debt-free and providing financial visibility/runway through early 2028.
TG4050 Phase I — Strong Disease-Free Survival Signal
In Phase I (adjuvant, HPV-negative head and neck cancer) all patients who received TG4050 remained disease-free after at least 2 years of follow-up (reported as 100% disease-free survival in the treated cohort), while the control arm experienced 3 relapses; trial met safety and feasibility endpoints.
TG4050 Immunogenicity and Durability
TG4050 induced neoantigen-specific T cell responses in 73% of evaluable patients; these immune responses were reported as durable, persisting 24 months after treatment initiation, with cytotoxic and effector phenotype markers observed up to 1 year after end of treatment. Phase I translational data published as a preprint and under journal review.
Progress to Randomized Phase II and Upcoming Milestones
Randomized Phase II portion of the Phase I/II trial is close to full randomization; primary endpoint is 2-year disease-free survival (regulatory-recognized). Expect first Phase II immunogenicity data in H2 2026, Phase I 3-year DFS data in Q2–Q3 2026, and Phase I 4-year follow-up in Q2–Q3 2027.
Positive Early Data for BT-001 Combination
BT-001 (intratumoral oncolytic virus, with BioInvent) in combination with pembrolizumab showed positive abscopal and sustained antitumor activity in both injected and non-injected lesions at ESMO 2025, consistent with the mechanistic hypothesis of converting cold tumors to hot tumors.
Manufacturing and Regulatory Preparedness Efforts
Active investments into manufacturing optimization, improved turnaround times, and preparation for increased production volumes; plan to have full GMP manufacturing by Q3 2027 to enable potential pivotal trials and strengthen partnering appeal.
Clear Strategic Focus and Execution Path
Company articulated focused priorities on TG4050/myvac platform, expansion to a second indication (Phase I planned to start in 2026), multiple meaningful milestones over the next 24 months, and an intent to engage with partners as value is created.
FR:TNG Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
FR:TNG Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 24, 2026 | €0.74 | €0.74 | +0.54% |
Nov 04, 2025 | €1.36 | €1.48 | +8.46% |
Sep 16, 2025 | €1.16 | €1.10 | -4.76% |
Apr 24, 2025 | €0.60 | €0.61 | +2.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Transgene SA (FR:TNG) report earnings?
Transgene SA (FR:TNG) is schdueled to report earning on Apr 29, 2026, During Market Hours (Confirmed).
What is Transgene SA (FR:TNG) earnings time?
Transgene SA (FR:TNG) earnings time is at Apr 29, 2026, During Market Hours (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Transgene SA stock?
The P/E ratio of Transgene is N/A.
What is FR:TNG EPS forecast?
Currently, no data Available